MICROALBUMINURIA AND LEFT VENTRICULAR GEOMETRY IN ESSENTIAL ARTERIAL HYPERTENSION

##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Vol. 87 No. 2 (2009): Issue Feb 2009

##plugins.themes.academic_pro.article.main##

R. Lakhdhar
Service de Cardiologie CHU La Rabta Tunis
F. Jarraya
Service de Néphrologie
H. Drissa
Service de Cardiologie CHU La Rabta Tunis
J. Hachicha
Service de Néphrologie
S Kammoun
Service de Cardiologie - CHU Hédi Chaker Sfax

Abstract

The association between left ventricular hypertrophy and microalbumiuria is actually admitted. Recent studies shown that patients with microalbuminuria have higher left ventricular mass index, worst systolic function and often concentric geometric kind of left ventricular hypertrophy. The efficiency of an adapted and early therapeutic on a potential relation sheep between reduction of microalbuminuria and improvement of target organ injury, principally heart and kidney, is still to evaluate.
The aim of our study is to review geometric and hemodynamic aspect of left ventricular hypertrophy in hypertensive microalbuminuric patients.

Keywords:

Microalbuminuria, left ventricular hypertrophy, hypertension

##plugins.themes.academic_pro.article.details##

References

  1. Pontremoli R , Nicolelle C, Viazzi F et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1998; 11: 430-8
  2. Redon J et al. Microalbuminuria is correlated with left ventricular hypertrophy in male hypertensive patients. J Hypertens 1991;9: S 148-S9
  3. Abergel E, Cohen A, Gueret P, Roudaut R. Echocardiographie clinique de l'adulte ESTEM;Vol (2) ; 929-34
  4. Wang TJ, Evans JC, Meigs JB et al. Low- grade albuminuria and the risks of hypertension and blood pressure progression. Framingham Heart Study. Circulation 2005;111: 1370-6
  5. Hornych A, Marre M, Mimran A, Chaignon M, Asmar R et fauvel J-P. Microalbuminurie dans l'hypertension artérielle : mesure, variations, interprétations, recommandations. Archive Mal c?ur 2000 ; 93 : 1304-8
  6. Nakahara T, Takata Y, Hirayama Y, Asano K, Adachi H, Shiokawa G, Sumi T, Ogawa T, Yamashina A.Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-t
  7. Pontremoli R, Sofia A, Ravera M et al. Prévalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC study. Hypertension 1997;30:1135 -43
  8. Carasola G, Cottone S, D'ignoto G et al. Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens suppl 1989 ; 1:S 1190-2
  9. Karthikeyan VJ, Bakris G, MacFadyen RJ.The advance trial: further PROGRESS With HOPE. JHum Hypertension 2007; 21: 911-3
  10. Watehtell K, Ibsen II, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy. The LIFE study. Ann Intern Med 2003; 139: 901-6.
  11. Romundstad S, Holmen J, Hallan H et al. Microalbuminuria and allcause mortality in treated hypertensive individuals. Does sex matter? Circulation 2003; 108: 783-9
  12. 1Luque M , Martell N, Egocheaga I et al. Left ventricular geometric patterns after 1 year of anti hypertensive treatment. J Clin Hypertension 2005 ; 7: 333-8
  13. Viazzi E, Leoncini G, Parodi G et al. Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. J Am Soc Nephrol 2005; Mars, 16suppl 1: 389-91
  14. Djoussé L, Kochar J, Hunt SC et al. Relation of albuminuria to left ventricular mass (from the HyperGEN Study). Am J Cardiol. 2008; 15;101:212-6.
  15. Lieb W, Mayer B, Stritzke J, Doering A, Hense HW, Loewel H, Erdmann J, Schunkert H. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONlCA/KORA Augsburg Echocardiographic Substudy. N
  16. Okin PM, Wachtell K, Devereux RB. LIFE Study lnvestigators. Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. Am J Hypertens 2008;3:273-9
  17. Tsioufis C, Dimitriadis K, Stefanadis C, Kallikazaros L. The emerging role of subclinical inflammation in hypertensionassociated early renal dysfunction: focus on microalbuminuria. J Cardiol 2006;47 :361-5
  18. Pontremoli R, Ravera M, Bezante GP et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999; 17: 993-1000.
  19. Assadi F. Relation of left ventricular hypertrophy of microalbuminuria and C reactive protein in children and adolescents with hypertension. Pediatr Cardio 2008; 29 : 580-40
  20. Dahlof B, Deveureux RB, Kjeldsen SE et al, For the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003
  21. Luque M, de Rivas B, Alvarez B, Garcia G, Fernandez C. Influence of target organ lesion detection (assesssment of microalbuminuria and echocardiogram) in cardiovascular risk stratification and treatment of untreated hypertensive patients. J Hum Hypert